Literature DB >> 9316837

3H-morphine-6beta-glucuronide binding in brain membranes and an MOR-1-transfected cell line.

G P Brown1, K Yang, O Ouerfelli, K M Standifer, D Byrd, G W Pasternak.   

Abstract

Morphine-6beta-glucuronide (M6G) is a potent morphine metabolite. In an effort to further explore its mechanisms of action, we synthesized 3H-M6G of high specific activity and examined its binding. Although its affinity toward traditional mu receptors is similar to morphine in binding assays in brain and in Chinese hamster ovary cells stably transfected with MOR-1, M6G is >100-fold more potent than morphine in analgesic assays. This apparent discrepancy cannot be explained by differing intrinsic activities of the two drugs because both agents are partial agonists with similar efficacies in adenylyl cyclase assays in the transfected cell lines. Behavioral studies have implied the possibility of a distinct M6G receptor. Detailed binding studies in brain tissue reveal evidence for heterogeneity. Nonlinear regression analysis of 3H-M6G saturation studies reveals two components. The lower-affinity component (K(D) = 1.93 +/- 0.6 nM) corresponds to labeling of traditional mu receptors. In addition, 3H-M6G labels another site of low abundance with very high affinity (K(D) = 68 +/- 7 pM). Competition studies indicate that both sites are relatively mu selective. However, several compounds clearly distinguish between the two sites. These binding studies support the concept of a unique M6G receptor responsible for its analgesic activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9316837

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Morphine-6 beta-glucuronide has a higher efficacy than morphine as a mu-opioid receptor agonist in the rat locus coeruleus.

Authors:  P B Osborne; B Chieng; M J Christie
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Induction of morphine-6-glucuronide synthesis by heroin self-administration in the rat.

Authors:  Maria Meringolo; Valentina Brusadin; Maria T De Luca; Christian Montanari; Christian L Montanari; Letizia Antonilli; Paolo Nencini; Aldo Badiani
Journal:  Psychopharmacology (Berl)       Date:  2011-10-21       Impact factor: 4.530

3.  HPLC with laser-induced native fluorescence detection for morphine and morphine glucuronides from blood after immunoaffinity extraction.

Authors:  Y Hupka; J Beike; J Roegener; B Brinkmann; G Blaschke; H Köhler
Journal:  Int J Legal Med       Date:  2005-01-19       Impact factor: 2.686

Review 4.  Morphine-6-glucuronide: an analgesic of the future?

Authors:  J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Codeine and 6-acetylcodeine analgesia in mice.

Authors:  Steven Milo; Michael Ansonoff; Michael King; Grace C Rossi; Amy Zuckerman; John Pintar; Gavril W Pasternak
Journal:  Cell Mol Neurobiol       Date:  2006-07-26       Impact factor: 5.046

6.  Effects of chronic opioid exposure on guinea pig mu opioid receptor in Chinese hamster ovary cells: comparison with human and rat receptor.

Authors:  Michael Wallisch; Cole S Nelson; Julia M Mulvaney; Heather S Hernandez; Sue Ann Smith; George D Olsen
Journal:  Biochem Pharmacol       Date:  2007-02-12       Impact factor: 5.858

Review 7.  Alternative Pre-mRNA Splicing of the Mu Opioid Receptor Gene, OPRM1: Insight into Complex Mu Opioid Actions.

Authors:  Shan Liu; Wen-Jia Kang; Anna Abrimian; Jin Xu; Luca Cartegni; Susruta Majumdar; Patrick Hesketh; Alex Bekker; Ying-Xian Pan
Journal:  Biomolecules       Date:  2021-10-15

Review 8.  Exploring Pharmacological Functions of Alternatively Spliced Variants of the Mu Opioid Receptor Gene, Oprm1, via Gene-Targeted Animal Models.

Authors:  Wenjian Kang; Shan Liu; Jin Xu; Anna Abrimian; Ayma F Malik; Raymond Chien; Adejuyigbe Adaralegbe; Akwasi Amponsah; Luca Cartegni; John Pintar; Ying-Xian Pan
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.